MNS16A Tandem Repeats Minisatellite of Human Telomerase Gene and Cancer Risk: A Meta-Analysis

Xiaoping Xia1*, Rui Rui2*, Sheng Quan3, Rong Zhong2, Li Zou2, Jiao Lou2, Xuzai Lu2, Juntao Ke2, Ti Zhang2, Yu Zhang2, Li Liu4, Jie Yan5*, Xiaoping Miao2*

1 Clinical Laboratory of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China, 2 State Key Laboratory of Environment Health (Incubation), MOE (Ministry of Education) Key Laboratory of Environment & Health, Ministry of Environmental Protection Key Laboratory of Environment and Health (Wuhan), and Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 3 Departments of Clinical Medicine, Zhejiang University City College, Hangzhou, Zhejiang Province, China, 4 Departments of Epidemiology and Biostatistics, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China, 5 Faculty of Basic Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China

Abstract

Background: Researchers have provided evidence that telomere dysfunction play an important role in cancer development. MNS16A is a polymorphic tandem repeats minisatellite of human telomerase (hTERT) gene that influences promoter activity of hTERT and thus implicates to relate with risk of several malignancies. However, results on association between MNS16A and cancer risk remain controversial. We therefore conduct a meta-analysis to derive a more precise estimation of association between MNS16A and cancer risk.

Methods: A systematic literature search was conducted by searching PubMed, ISI Web of Knowledge, Human Genome and Epidemiology Network Navigator and Google Scholar digital database for publications on associations between MNS16A and cancer risk. Variants with statistically significant associations by meta-analysis were assessed using Venice criteria.

Results: 10 case-control articles enrolling 6101 cases and 10521 controls were brought into our meta-analysis. The relationships were strong epidemiological credibility in cerebral cancer and breast cancer population (P for heterogeneity > 0.1). The cumulative analysis in chronologic order suggested a clear tendency towards a significant association with additional study samples.

Conclusions: The results provided a more accurate depiction of the role of MNS16A in cerebral cancer and breast cancer susceptibility. Additional larger studies were warranted to validate our findings.

Introduction

Telomeres (a distinctive DNA-protein structure at the distal end of eukaryotic chromosomes) are crucial for genomic stability [1–5]. Somatic cells have a progressive shortening of telomeres after each cell division, however, telomerases reach a critical short length and lose capping function at the senescence stage in immortal tumor cells. Uncapped chromosomal ends will then trigger DNA-damage-like responses [6,7]. The expressions of telomerase can prevent the loss of telomeres [8–10]. Human telomerase reverse transcriptase (hTERT) as the key constituent of telomerase, is highly expressed in essentially all immortal tumor cells, but is restricted in normal tissues, leading investigators to consider hTERT as a critical role with cancer susceptibility [11–13]. MNS16A, a polymorphic tandem repeats minisatellite in downstream of hTERT gene, has been first reported to affect promoter activity in lung cancer cell lines [14]. The variants containing short tandem repeats (S allele) have stronger promoter activity than long repeats (L allele), indicating number of tandem repeats associated with lung cancer risk. Subsequently, several malignancies such as cerebral [15,16], lung [17,18], breast [19,20], colorectal [21], nasopharyngeal [22], prostate cancer [23] and one meta-analysis [24] had investigated MNS16A in the etiology of cancer but with inconsistent results. Considering the important role of MNS16A in promoter activity of hTERT gene, we therefore conduct a meta-analysis on eligible articles to estimate association of MNS16A with cancer risk.

Materials and Methods

Search strategy, eligibility criteria and data extraction

All methodology was based on guidelines proposed by the Human Genome Epidemiology Network (HuGENet) [25] and the Preferred Reporting Items for Systematic Reviews and Meta-
Table 1. Characteristics for case-control studies of MNS16A and risk of cancer included in a meta-analysis.

| First author | Year | Study location | Ethnicity | Mean age case | Mean age control | Source | Cancer type | No. of case/ control | No. of LS* case/ control | No. of SS* case/ control |
|--------------|------|----------------|-----------|---------------|------------------|--------|-------------|---------------------|------------------------|------------------------|
| Wang [14]    | 2003 | USA            | Caucasian | 65.5          | 54.9             | hospital | NSCLC       | 53/72               | 30/33                  | 17/29                  |
| Carpentier [16] | 2007 | France         | Caucasian | 56.3          | 49.0             | population | GBM        | 205/305             | 69/133                 | 111/144                | 25/28                  |
| Wang [19]    | 2008 | China          | Asian     | 51.71         | 51.77            | population | BC         | 1006/1095          | 860/984                | 141/107                | 5/4                    |
| Andersson [15] | 2009 | Europe         | Caucasian | 47            | 51               | population | Glioma     | 648/1359           | 282/650                | 277/560                | 89/149                 |
| Jin [18]     | 2010 | Korea          | Asian     | 61.7          | 61.5             | population | NSCLC      | 937/943            | 820/840                | 110/101                | 7/2                    |
| Hofer [21]   | 2011 | Austria        | Caucasian | 66.8          | 61.3             | population | CRC        | 88/1712            | 36/770                 | 44/747                 | 8/195                  |
| Zhang [22]   | 2011 | China          | Asian     | NA            | NA               | population | NPC        | 798/1019           | 725/891                | 71/121                 | 2/7                    |
| Chang [17]   | 2011 | Taiwan         | Asian     | 67.58         | 67.09            | population | NSCLC      | 205/219            | 181/197                | 24/21                  | 0/1                    |
| Zagouri [20] | 2012 | Greece         | Caucasian | 55.1          | 55.7             | hospital   | BC         | 113/124            | 50/63                  | 36/29                  | 27/32                  |
| Hofer [23]   | 2013 | Austria        | Caucasian | 63.8          | 67.4             | hospital   | PC         | 1137/650           | 501/308                | 499/277                | 137/65                 |

*a,b,c* The length of MNS16A were defined as L allele or S allele under LS classification system.

Abbreviation: NA, none anonymous; GBM, glioblastoma; BC, breast cancer; NSCLC, non-small cell lung cancer; CRC, colorectal cancer; NPC, nasopharyngeal cancer; PC, prostate cancer.

doi:10.1371/journal.pone.0073367.t001
Analyses (PRISMA) [26] for systematic review of genetic association studies. A systematic review of original publications analyzing the association between MNS16A and cancer risk was performed by searching PUBMED, ISI Web of knowledge and Google Scholar database on and before February 2013, without language restriction. The strategy of keywords were: ("Neoplasm"[Mesh] OR "Carcinoma"[Mesh]) AND ("Telomerase"[Mesh] OR hTERT) AND MNS16A. Furthermore, we screened the Human Genome and Epidemiology Network Navigator as well as the references lists of key studies and reviews for additional publications [27]. We then performed the following criteria for literature selection: (a) original relevant case-control articles were included in this paper; (b) articles dealing with association between MNS16A and cancers in humans were available; (c) articles providing sufficient data to calculate ORs and 95% confidence intervals (CIs) were considered eligible. Information was extracted independently by two investigators (Rui and Zou) to ensure homogeneity of data collection and to rule out subjectivity effect in data gathering and entry. The following data should be noted: first author’s name, published year, location where the study was conducted.

Table 2. Pooled ORs with 95% CIs for the association between MNS16A and cancer risk in meta-analysis.

| Category          | Genetic model       | ORs (95% CI) | P    | P for I² | Heterogeneity |
|-------------------|---------------------|--------------|------|----------|---------------|
| LS classification | S vs. L             | 1.13 (1.03–1.25) | 0.013 | 0.012    | 53.3%         |
| (No. of study = 13) | LS vs. LL          | 1.15 (1.03–1.28) | 0.015 | 0.102    | 35.0%         |
|                   | SS vs. LL           | 1.32 (1.14–1.53) | 0.000 | 0.337    | 10.8%         |
|                   | L vs. LL            | 1.17 (1.05–1.31) | 0.006 | 0.064    | 40.5%         |
|                   | Recessive           | 1.23 (1.07–1.41) | 0.003 | 0.307    | 13.7%         |
| LMS classification | S vs. L             | 1.21 (1.04–1.41) | 0.015 | 0.047    | 50.8%         |
| (No. of study = 8) | M vs. L             | 1.04 (0.75–1.42) | 0.830 | 0.041    | 52.1%         |
|                   | LM+MM vs. LL        | 1.04 (0.73–1.50) | 0.823 | 0.003    | 54.8%         |
|                   | LM+MM vs. LL        | 1.04 (0.73–1.50) | 0.823 | 0.003    | 54.8%         |
|                   | LM+MM vs. LL        | 1.04 (0.73–1.50) | 0.823 | 0.003    | 54.8%         |
|                   | LM+MM vs. LL        | 1.04 (0.73–1.50) | 0.823 | 0.003    | 54.8%         |
|                   | LM+MM vs. LL        | 1.04 (0.73–1.50) | 0.823 | 0.003    | 54.8%         |

*a* P value was calculated by the Z test.

*b* The length of MNS16A was defined as L, M or S allele under LMS classification system.

Figure 2. Forest plot of MNS16A association with cancer risk under dominant model stratified by ethnicity.

doi:10.1371/journal.pone.0073367.t002

doi:10.1371/journal.pone.0073367.g002
conducted, ethnicity, study period, mean age of case and control, source population, cancer type, sample size, variant counts in both cases and controls. For studies investigating more than one type of cancer, data were extracted separately as independent study source populations. The estimated variance was calculated by the Cochrans Q statistic test and \( I^2 \) statistic (to assess whether observed variance exceeds expected variance). And for the \( I^2 \) metric \( (I^2 = 100\% \times (Q_{df})/Q) \), the following cut-off points were used: \( I^2 = 0–25\% \), no heterogeneity; \( I^2 = 25–50\% \), moderate heterogeneity; \( I^2 = 50–75\% \), large heterogeneity; \( I^2 = 75–100\% \), extreme heterogeneity. The significance of the combined ORs was determined using the \( Z \) test (\( P < 0.05 \) was considered statistically significant). The DerSimonian and Laird random effect model [29] was used to calculate pooled ORs and 95% CIs according to their heterogeneity, otherwise, a fixed effects model (the Mantel-Haenszel method) was applied. Stratified analysis was performed for two ethnicity groups in order to investigate the hypothesis of ethnicity-specific genetic mechanisms in the development of MNS16A. Summary ORs and 95% CIs were also calculated after stratification for cancer type. Additionally, sensitivity analysis was performed consecutively by omitting every article from the meta-analysis in turn to determine the influence of each study on the overall estimate [30]. Cumulative meta-analysis was performed through an assortment of all eligible cancer studies within the publication years. Finally, publication bias was evaluated by Begg’s test and Egger’s test to detect the small study effect [31]. All statistical analyses were performed with STATA software (version 10.1), and a 2-sided \( P \) value of less than \( P < 0.05 \) was considered significant, except for \( Q \) test for heterogeneity, for which a less than 0.1 level of statistical significance was applied.

### Sensitivity analyses and between-study heterogeneity

Between-study heterogeneity was assessed by the 2-based Cochran’s \( Q \) statistic test and \( I^2 \) metric [28]. Heterogeneity was considered significant at \( P < 0.1 \) for the \( Q \) statistic (to assess whether observed variance exceeds expected variance). And for the \( I^2 \) metric \( (I^2 = 100\% \times (Q_{df})/Q) \), the following cut-off points were used: \( I^2 = 0–25\% \), no heterogeneity; \( I^2 = 25–50\% \), moderate heterogeneity; \( I^2 = 50–75\% \), large heterogeneity; \( I^2 = 75–100\% \), extreme heterogeneity. The significance of the combined ORs was determined using the \( Z \) test (\( P < 0.05 \) was considered statistically significant). The DerSimonian and Laird random effect model [29] was used to calculate pooled ORs and 95% CIs according to their heterogeneity, otherwise, a fixed effects model (the Mantel-Haenszel method) was applied. Stratified analysis was performed for two ethnicity groups in order to investigate the hypothesis of ethnicity-specific genetic mechanisms in the development of MNS16A. Summary ORs and 95% CIs were also calculated after stratification for cancer type. Additionally, sensitivity analysis was performed consecutively by omitting every article from the meta-analysis in turn to determine the influence of each study on the overall estimate [30]. Cumulative meta-analysis was performed through an assortment of all eligible cancer studies within the publication years. Finally, publication bias was evaluated by Begg’s test and Egger’s test to detect the small study effect [31]. All statistical analyses were performed with STATA software (version 10.1), and a 2-sided \( P \) value of less than \( P < 0.05 \) was considered significant, except for \( Q \) test for heterogeneity, for which a less than 0.1 level of statistical significance was applied.

### Estimating the credibility of statistically significant associations

Each variant with statistically significant associations by meta-analysis were assessed on the basis of the Human Genome Epidemiology Network Venice criteria. Credibility was
defined as “strong,” “moderate,” or “weak” based on grades A, B, or C in three categories: 1) amount of evidence; 2) replication; and 3) protection from bias. Amount of evidence was assessed by size of test allele among case and controls in meta-analysis (nminor): grade A, B, C requires nminor > 1000, 100 ≤ nminor ≤ 1000, nminor < 100. Replication was graded by the heterogeneity statistic: grades A, B, and C were assigned for I² less than 25%, 25–50%, and greater than 50%, respectively. Assessment of protection from bias was graded as grade A if there was no observable bias, grade B if bias could be present, or grade C if bias was evidence (the presence of a summary ORs less than 1.15 or loss of statistical significance after excluding the initial study) [32].

Results

Subjects characteristics

After comprehensive searching of 71 articles, we identified 10 relevant publications including 6101 cases and 10521 controls from 13 studies to assess the association between MNS16A and cancer risk (Figure 1): 2 studies focused on glioblastoma [15,16], 2 studies focused on glioma [15,16], 3 studies focused on non-small cell lung cancer [14,17,18], 2 studies focused on breast cancer [19,20] and each was one for meningioma [15], colorectal carcinoma [21], nasopharyngeal carcinoma [22] and prostate cancer [23] (Table 1). All studies were case-control studies, of which the most frequently investigated was brain cancer (6451 subjects; 38.81%). Among these, 9 studies were conducted in Caucasians (10400 subjects; 62.57%) and 4 in Asians (6222 subjects; 37.43%).

Results of the meta-analysis

As shown in Table 2, all studies were pooled into a meta-analysis, and the increased association between MNS16A and cancer risk were found for all genotypic models. Random-effect model pooling analyses yielded overall ORs of 1.15 (95% CI = 1.03–1.28; P for heterogeneity = 0.102, I² = 35.0%) for LS genotype versus LL genotype, and 1.17 (95%CI = 1.05–1.31; P for heterogeneity = 0.064, I² = 40.5%) for dominant model. In fixed-effects model, overall ORs were 1.32 (95%CI = 1.14–1.53; P for heterogeneity = 0.337, I² = 10.8%) for SS genotype versus LL genotype, and 1.23 (95% CI = 1.07–1.41; P for heterogeneity = 0.307, I² = 13.7%) for recessive model.

Subsequently we categorized the data in LMS classification described by Jin et al. to explore in depth the effect of MNS16A S allele (the short allele) and M allele (the middle allele) with cancer risk. As shown in Table 2, 8 studies were classified during LMS classification system. All genetic models revealed that S allele presented a great cancer risk than M allele and 95%CIs were nearby statistically significant.

Stratified analysis

Stratified analysis was performed for two ethnicity groups in order to investigate the hypothesis of Asian and Caucasian genetic mechanisms in the development of MNS16A. (Table 3). No evidence of heterogeneity was revealed in Caucasian population (P for heterogeneity > 0.1), and all genetic models presented a significantly increased cancer risk, with ORs of 1.16 (95%CI = 1.05–1.28), 1.33 (95%CI = 1.15–1.54), 1.19 (95%CI = 1.09–1.31) and 1.23 (95%CI = 1.07–1.42) for LS versus
LL genotype, SS versus LL genotype, dominant model, and recessive model, respectively. However, all genetic models presented no statistical differences of cancer risk among Asian population (Figure 2).

Then, we assessed the source of heterogeneity by cancer type (Table 3). On the basis of five cerebral cancer studies, there was no heterogeneity for all genetic models ($P$ for heterogeneity $>0.1$). Patients with MNS16A-S allele had a significant statistically association with cerebral cancer risk: with ORs of 1.42 ($95\%\text{CI}=1.19–1.70$), 1.22 ($95\%\text{CI}=1.09–1.37$), 1.32 ($95\%\text{CI}=1.11–1.56$) for SS versus LL genotype, dominant and recessive model ($P$ for heterogeneity $>0.1$). For breast cancer, patients carried with LS genotype had higher risk than SS genotype, which ORs and 95%CI were 1.52 ($1.19–1.94$) and 1.46 ($1.16–1.84$) for LS versus LL genotype and dominant models. However, no statistically significant associations were observed with lung cancer patients (Figure 3).

Cumulative meta-analysis

Cumulative meta-analyses of MNS16A were conducted via an assortment of studies in chronologic order. Figure 4 shows the results from the cumulative meta-analyses in fixed-effects model. The effect of MNS16A tended to show a significant association over time in all genetic models. Moreover, the 95% CIs became increasingly narrow with increasing data, suggesting that the precision of the estimates was progressively boosted by continually adding more studies.

Sensitivity analysis

Since moderate heterogeneity was observed under the genotypic model of LS versus LL and dominant models, we conducted a sensitivity meta-analysis to assess effects of each study on the combined ORs and 95% CIs. A random-effect model was employed since heterogeneity was indicated. Sensitivity analysis indicated the independent study contributing the most heterogeneity was conducted by Zhang et al. The heterogeneity was completely reduced by exclusion of that study: under the genotypic model of LS versus LL, ORs = 1.15 ($95\%\text{CI}=1.03–1.28$, $P$ for heterogeneity $=0.102$, $I^2=35.0\%$) and ORs = 1.20 ($95\%\text{CI}=1.10–1.31$, $P$ for heterogeneity $=0.656$, $I^2=0.00\%$) before and after removal, respectively. Omission of studies by Andersson et al. changed the pooled ORs fractionally (Table 4).

Publication bias

As reflected by either visualization of funnel plot or Egger’s and Begg’s test, there was no indication of publication bias in the genotypic models of LS versus LL, SS versus LL, dominant, and recessive model ($P=0.482$, $P=0.537$, $P=0.551$, and $P=0.745$, respectively), indicating the results were statistically robust.
Grading of associations

Based on the previously proposed guidelines and applying the Venice criteria, the amount of evidence was categorized as A, since its \( n_{\text{minor}} \) is above 1,000 (\( n_{\text{minor}} = 2558 \)); replication was assigned to category B, because the amount of between-study heterogeneity (\( I^2 = 40.5\% \)); and protection from bias was graded as category B, due to the presence of summary ORs less than 1.15, which can easily be dissipated even by relatively small biases in a meta-analysis of published data. The overall assessment of association between MNS16A and cancer risk were moderate cumulative evidence (ABB). After stratification by ethnicity, the meta-analysis consistently showed a significant association cancer risk in Caucasian population and were assigned an overall strong epidemiological credibility (AAA). Asian population lacked of statistically significant findings and was placed to weak evidence.

Comparison with previously published meta-analyses

In a meta-analysis that regarding all hTERT locus polymorphisms with cancer susceptibility, Simone et al. investigated that MNS16A S allele was statistically associated with increased risk of central nervous system tumors (CNS). In comparison, our meta-

---

**Table 4.** Pooled ORs with 95% CIs for the association between MNS16A and cancer risk by omitting each article in sensitivity analysis.

| First author | Year | Genetic model | ORs (95% CI) | \( p^a \) | \( p^b \) for heterogeneity | \( \hat{\rho} \) |
|--------------|------|---------------|--------------|--------|-----------------------------|-------|
| Wang [14]    | 2003 | LS vs. LL     | 1.16 (1.07–1.27) | 0.000  | 0.136                       | 31.8% |
|              |      | Dominant      | 1.19 (1.07–1.33) | 0.001  | 0.097                       | 36.7% |
| Carpentier [16] | 2007 | LS vs. LL     | 1.14 (1.01–1.29) | 0.028  | 0.091                       | 38.8% |
|              |      | Dominant      | 1.15 (1.02–1.30) | 0.023  | 0.053                       | 44.9% |
| Wang [19]    | 2008 | LS vs. LL     | 1.12 (1.03–1.23) | 0.009  | 0.224                       | 22.3% |
|              |      | Dominant      | 1.15 (1.06–1.25) | 0.001  | 0.122                       | 33.5% |
| Andersson [15] | 2009 | LS vs. LL     | 1.15 (0.97–1.36) | 0.103  | 0.034                       | 50.3% |
|              |      | Dominant      | 1.15 (0.98–1.37) | 0.187  | 0.023                       | 53.4% |
| Jin [18]     | 2010 | LS vs. LL     | 1.16 (1.03–1.31) | 0.017  | 0.076                       | 39.8% |
|              |      | Dominant      | 1.18 (1.04–1.33) | 0.009  | 0.044                       | 45.3% |
| Hofer [21]   | 2011 | LS vs. LL     | 1.15 (1.02–1.29) | 0.019  | 0.077                       | 39.5% |
|              |      | Dominant      | 1.18 (1.04–1.32) | 0.007  | 0.044                       | 45.3% |
| Zhang [22]   | 2011 | LS vs. LL     | 1.20 (1.10–1.31) | 0.000  | 0.656                       | 0.00% |
|              |      | Dominant      | 1.23 (1.13–1.33) | 0.000  | 0.719                       | 0.00% |
| Chang [17]   | 2011 | LS vs. LL     | 1.15 (1.03–1.29) | 0.016  | 0.075                       | 39.8% |
|              |      | Dominant      | 1.18 (1.05–1.32) | 0.006  | 0.044                       | 45.3% |
| Zagouri [20] | 2012 | LS vs. LL     | 1.15 (1.02–1.28) | 0.018  | 0.097                       | 36.7% |
|              |      | Dominant      | 1.17 (1.04–1.31) | 0.008  | 0.046                       | 45.0% |
| Hofer [23]   | 2013 | LS vs. LL     | 1.15 (1.02–1.31) | 0.027  | 0.074                       | 40.0% |
|              |      | Dominant      | 1.17 (1.03–1.33) | 0.015  | 0.044                       | 45.3% |

\(^a\)P value was calculated by the Z test.

**Table 5.** Assessment of cumulative evidence for the association of MNS16A dominant model and risk of cancer.

| No. of | No. of | ORs (95% CI) | \( P^a \) for case | \( P^b \) for control | \( \hat{\rho} \) | Level of evidence |
|--------|--------|--------------|---------------------|----------------------|-------|-----------------|
| Case   | Control|             | Z test              | Heterogeneity        |       |                 |
| Overall| 6101   | 10521        | 1.17 (1.05–1.31)    | 0.006                | 0.064 | 40.5% ABB/Moderate |
| Caucasian| 3155 | 7245         | 1.19 (1.09–1.31)    | 0.000                | 0.696 | 0.00% AAA/Strong  |
| Asian  | 2946   | 3276         | 1.10 (0.76–1.57)    | 0.621                | 0.003 | 78.7% Weak       |
| Cerebral Cancer| 1263 | 2974        | 1.22 (1.09–1.37)    | 0.000                | 0.686 | 0.00% AAA/Strong  |
| Lung Cancer| 177  | 157         | 1.07 (0.81–1.42)    | 0.627                | 0.229 | 32.2% Weak       |
| Breast Cancer| 1119 | 1219        | 1.46 (1.16–1.84)    | 0.002                | 0.620 | 0.00% AAA/Strong  |

Abbreviation: NSCLC, non-small cell lung cancer; A, B, and C represent the Venice criteria grades for amount of evidence, replication of association and protection from bias, which ultimately define the level of cumulative evidence (strong, moderate, weak).

\(^b\)doi:10.1371/journal.pone.0073367.t004
analysis added more publications to consider association of MNS16A with all available type of cancer; analyzed data in different MNS16A classification system (LS and LMS classification system); stratified ethnicity and cancer types for further research.

Discussion

A number of well designed genome wide association studies (GWAS) had implicated variants at hTERT locus to be significantly associated with almost all malignant tumors [33]. MNS16A, a 23 bp (or 26 bp) tandem repeat sequence (TCCTCTTAT (cat) CTCCCAGTCTC) in putative promoter region of the antisense RNA transcript, was first reported to increase expression of hTERT mRNA in lung cancer tissues. In the current study, we conducted a meta-analysis of 10 previously published articles comprising 6101 cases and 10521 controls concerning association of MNS16A with cancer risk. Although all genetic models of MNS16A showed a moderate association with cancer risk, the effect could very well be driven by the effect on cerebral cancer. Thereupon, we stratified cancer types and found cerebral cancer and breast cancer patients showed strong cumulative evidence for associations, but lung cancer was not. Apart from this, ethnicity was also stratified in this work. Caucasian population presented a significantly increased relationship with cancer risk, whereas Asians not. The variance of effect between Caucasians and Asians might be contributed to that approximate 70% Caucasians were cerebral cancer, while similarly the absence of effect in Asians might well be due to the fact that only non-cerebral cancer were carried in this population. In addition, there was almost no obviously heterogeneity by stratified for cancer type, which suggested differential effects of MNS16A in diverse kinds of cancer. However, functional importance of the antisense transcript activity and exact molecular mechanisms of MNS16A with different cancer types were still unclear.

In this work, we analyzed data in different classification system: LS and LMS (described by Hofer et al. [21]) classification system for further excavation. The results figured that S allele had higher relationship than M allele with MNS16A. The cause might due to length of MNS16A: M allele contains three 26 bp repeats; whereas S alleles contain two 26 bp repeats. Hence we could see that, 26 bp sequence may influence as a repressor for promoter of antisense TERT mRNA [18]. It is more reasonable to analysis MNS16A S allele and M allele separately in future research to find accurate genotype with cancer risk.

Through sensitivity analysis, omission of one article by Zhang et al. eliminated heterogeneity of LS versus LL genotype and dominant models (P for heterogeneity > 0.1). The reason might due to lower frequencies of S allele in Asians. Additionally, omission article by Carpentier, the ORs were still presented increased risk, and 95%CI were nearby statistically significant (OR = 1.15, 95%CI = 1.03–1.28; OR = 1.14, 95%CI = 1.01–1.29, before and after removal), which not meaningfully changed the pooled ORs, as well as the article by Andersson.

Some limitations needed serious consideration. First, our result was based on unadjusted estimates. Individual data were not available for an adjusted estimate by age and sex, which might potentially lead to false positive results. Another limitation was lacking original data to limit our further evaluation of gene-environment interaction such as smoking, alcohol use and other clinical characteristics. Finally, lacking of sufficient original studies limited our further evaluation of colorectal cancer, breast cancer and nasopharyngeal carcinoma risk with MNS16A.

Conclusion

This work verified the important role of MNS16A minisatellites in cerebral and breast cancer predisposition. Additional larger studies were warranted to validate our findings.

Supporting Information

Checklist S1

(DOC)

Acknowledgments

This work was copyedited by Helen Neumann from Cell Stress & Chaperones Editorial Office and Cell Stress Society International Dept. of Molecular & Cell Biology, University of Connecticut.

Author Contributions

Conceived and designed the experiments: XX RR SQ XM. Analyzed the data: RZ LZ JL XI JK TZ YZ LL JY XM. Wrote the paper: XX RR SQ XM.

References

1. Greider CW (1991) Chromosome first aid. Cell 67: 645–647.
2. Murnane JP (2006) Telomeres and chromosome instability. DNA Repair (Amst) 5: 1082–1092.
3. Ju Z, Rudolph KL (2006) Telomeres and telomerase in cancer stem cells. Eur J Cancer 42: 1197–1203.
4. Cong YS, Wright WE, Shih JY (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66: 497–425, table 13 contents.
5. Blackburn EH (2001) Switching and signaling at the telomere. Cell 106: 661–673.
6. Sathyanarayana A, Manns MP, Rudolph KL (2004) Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology 40: 276–283.
7. Vaziri H, Benchimol S (1996) From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging. Exp Gerontol 31: 295–301.
8. Kim NW, Patsyszek MA, Provse KR, Harley CB, West MD, et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011–2015.
9. Broccoli D, Young JW, de Lange T (1995) Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A 92: 9002–9006.
10. Lantuejoul S, Salon C, Soria JC, Brambilla E (2007) Telomerase expression in lung preneoplasia and neoplasia. Int J Cancer 120: 1035–1041.
11. Wick M, Zubov D, Hagen G (1999) Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 232: 97–106.
12. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, et al. (1995) The RNA component of human telomerase. Science 269: 1236–1241.
13. Stanta G, Bonin S, Nicolini R, Raccanelli A, Baralle F (1999) Catalytic subunit of telomerase expression is related to RNA component expression. FEBS Lett 460: 285–288.
14. Wang L, Soria JC, Chang YS, Lee HY, Wei Q, et al. (2003) Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer. Oncogene 22: 7123–7129.
15. Andersson U, Osterman P, Sjostrom S, Johansen C, Henriksson R, et al. (2009) MNS16A minisatellite genotypes in relation to risk of gloma and meningoma and to glioblastoma outcome. Int J Cancer 125: 960–972.
16. Carpentier C, Lejeune J, Gros F, Everhard S, Marie Y, et al. (2007) Association of telomerase gene hTERT polymorphism and malignant gliomas. J Neurooncol 84: 249–253.
17. Chang CC, Yu MC, Bai KJ, Chang JH, Lee CN, et al. (2011) The Analysis Between Functional Human Telomerase Reverse Transcriptase MNS16A Polymorphisms and the Risk of Developing Non-Small Cell Lung Cancer in the Taiwanese Population. Journal of Experimental and Clinica I Medicine 3: 3.
18. Jin G, Yoo SS, Cho S, Jeon HS, Lee WK, et al. (2011) Dual roles of a variable number of tandem repeat polymorphism in the TERT gene in lung cancer. Cancer Sci 102: 144–149.
19. Wang Y, Hu Z, Liang J, Wang Z, Tang J, et al. (2008) A tandem repeat of human telomerase reverse transcriptase (hTERT) and risk of breast cancer development and metastasis in Chinese women. Gancrcogenesis 29: 1197–1201.
20. Zagouri F, Sergentanis TN, Gazouli M, Tsigginou A, Dimitrakakis C, et al. (2012) HTERT MNS16A polymorphism in breast cancer: a case-control study. Mol Biol Rep 39: 10859–10863.

21. Hofer P, Baierl A, Feik E, Fuhringer G, Leeb G, et al. (2011) MNS16A tandem repeats minisatellite of human telomerase gene: a risk factor for colorectal cancer. Carcinogenesis 32: 866–871.

22. Zhang Y, Zhang H, Zhai Y, Wang Z, Ma F, et al. (2011) A functional tandem-repeats polymorphism in the downstream of TERT is associated with the risk of nasopharyngeal carcinoma in Chinese population. BMC Med 9: 106.

23. Hofer P, Zerelles J, Baierl A, Madersbacher S, Schatzl G, et al. (2013) MNS16A tandem repeats minisatellite of human telomerase gene and prostate cancer susceptibility. Mutagenesis.

24. Mocellin S, Verdi D, Pooley KA, Landi MT, Egan KM, et al. (2012) Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J Natl Cancer Inst 104: 840–854.

25. Sagoo GS, Little J, Higgins JP (2009) Systematic reviews of genetic association studies. Human Genome Epidemiology Network. PLoS Med 6: e28.

26. Swartz MK (2011) The PRISMA statement: a guideline for systematic reviews and meta-analyses. J Pediatr Health Care 25: 1–2.

27. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ (2008) A navigator for human genome epidemiology. Nat Genet 40: 124–125.

28. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.

29. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.

30. Tobias A (1999) Assessing the influence of a single study in meta-analysis. Stata Technical Bulletin 8: 7.

31. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.

32. Langevin SM, Ioannidis JP, Vinei P, Taal E (2010) Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines. Pharmacogenet Genomics 20: 586–597.

33. Baird DM (2010) Variation at the TERT locus and predisposition for cancer. Expert Rev Mol Med 12: e16.